Close Menu

George Church, David Walt, Kevin Chen

Jul 24, 2018

Molecular diagnostics firm NuProbe Global has formed a scientific advisory board and appointed a new member to its board of directors. The firm has named George Church and David Walt as members of the scientific board. Church and Walt are currently professors of genetics and pathology, respectively, at Harvard Medical School. The firm has also appointed Kevin Chen, founding partner at Biotrack Capital, as a member of the board of directors. Chen has previously led investment in healthcare companies including Beijing Genomics Institute (BGI), Betta Pharma, and Yuwell Medical. 

More Like This

Dec 12, 2019

Admera Health: Omar Karame

Admera Health has appointed Omar Karame as CFO. Karame was previously CFO of an energy technology company. He also previously spent several years in private equity, venture capital, and investment banking working on healthcare transactions. He received an MBA from the Wharton Business School and BA from Dartmouth College.

Dec 12, 2019

Digital Pathology Association: Michael Rivers

The Digital Pathology Association announced Michael Rivers has been named its new president, effective Jan. 1, 2020. Rivers is currently the vice president of Roche Digital Pathology and has been the head of the division since 2015, leading the digital pathology teams in California and Arizona. He joined Roche Tissue Diagnostics in 2006. Rivers will replace outgoing DPA President Marilyn Bui. 

Dec 11, 2019

10x Genomics: Paul Conley

Paul Conley has resigned from 10x Genomics' board of directors, effective immediately. In a document filed with the US Securities and Exchange Commission, 10x said Conley's decision "was due solely to time commitments and a personal decision to pursue other business opportunities and is not due to any disagreement with the company's management team, operations, financial statements, policies, or procedures."

Dec 11, 2019

NIH: Joshua Denny, Eric Dishman, Stephanie Devaney

Joshua Denny has been selected as CEO of the US National Institutes of Health's All of Us research program. He will replace Eric Dishman, who will become chief innovation officer for the program. Denny is currently a professor in the departments of Biomedical Informatics and Medicine at Vanderbilt University Medical Center. He is also the principal investigator for the All of Us Data and Research Center, and he was a member of an advisory committee to the NIH director that helped develop the All of Us program.

Stephanie Devaney, currently deputy director for the All of Us program, is being promoted to chief operating officer, a new position.

Dec 11, 2019

Stilla Technologies: Khaled Bahi, Jerome Leclercq, Quang Tran

Stilla Technologies has added Khaled Bahi as chief financial officer, Jerome Leclercq as senior vice president for commercial operations Europe and Asia, and Quang Tran as quality and regulatory affairs director.

Bahi has more than 20 years of experience in the medtech industry in finance and operations roles, previously serving as CFO of the Swiss cardiovascular company Symetis, which was acquired by Boston Scientific. Leclercq has more than 30 years of experience in the commercialization of advanced technologies in the life sciences and previously held senior positions at Gilson and PerkinElmer. Tran has more than 20 years experience in the medtech and biotech industries in quality, regulatory, and operating roles, with previous positions at BioSerenity and Becton Dickinson, among others.

Dec 10, 2019

Biotia: Barry Zeman, Don Goldmann, Steven Salzberg

Biotia has added Barry Zeman, Don Goldmann, and Steven Salzberg to its scientific and clinical advisory board. Zeman is chief strategy officer and vice chairman of inpatient psychiatric hospital organization Assurance Health System, as well as chief stategy officer of telehealth company MedSign. Goldmann is an epidemiologist at the Harvard T.H. Chan School of Public Health and CSO emeritus for the Institute for Healthcare Improvement, a Boston-based patient safety organization. Salzberg is director of the Center for Computational Biology in the McKusick-Nathans Institute of Genetic Medicine at Johns Hopkins University.

Dec 09, 2019

Roche: Andreas Oeri, John Bell

Roche announced Andreas Oeri will retire from the company's board of directors in 2020, to be replaced by Jörg Duschmalé. Oeri was previously chairman of the company's corporate governance and sustainability committee. Also, the company said that John Bell will not stand for reelection to the board in 2020, and the board has proposed Patrick Frost, CEO of the Swiss Life Group, for his replacement. 

Additionally, Gottlieb Keller, Roche's general counsel, a member of the corporate executive committee, and the board's secretary, will retire in March 2020 after 35 years at the company. Claudia Böckstiegel, who is currently the head of legal of Roche's diagnostics division, will take over as general counsel. On April 1, 2020, she will also become a member of the Enlarged Corporate Executive committee. Annette Luther, the current general manager of Roche Diagnostics International, will be the new secretary to the board. 

Dec 06, 2019

Bionano Genomics: Quan Zhou

Quan Zhou resigned from the Bionano Genomics board of directors, effective Dec. 12. In a document filed Dec. 6 with the US Securities and Exchange Commission, Bionano Genomics said the resignation "is not the result of any disagreement with the company." 

Dec 06, 2019

Insitro: Serafim Batzoglou

Serafim Batzoglou has become chief data officer of San Francisco-based drug discovery and development firm Insitro. He joins the company from Illumina, where he was VP of applied and computational biology. Prior to that, he was a professor of computer science at Stanford University. He is also a cofounder of DNAnexus. Batzoglou holds a PhD in computer science, a master's degree in electrical engineering, and a BS in mathematics and computer science from MIT.

Dec 06, 2019

Centogene: Philip Lambert, Peter Bauer

Philip Lambert has become CSO of Centogene, replacing Peter Bauer, who is now the firm's chief genomic officer. Lambert joins the company from Life Biosciences, where he was senior VP of discovery and labs as well as chief operating officer of two subsidiaries, Selphagy Therapeutics and Spotlight Biosciences. Prior to that, he was scientific partner and head of discovery at Charles River Laboratories. He also cofounded preclinical screening firm VivoPath. Lambert holds a PhD in neuropharmacology from Imperial College London and a BSc in pharmacology from the University of Liverpool.

Dec 02, 2019

NeoGenomics: Lawrence Weiss

NeoGenomics has appointed Lawrence Weiss as the company's chief medical officer, effective Nov. 25. He has been NeoGenomics' CSO since December 2018. Prior to that, he had been the firm's director of pathology services since March 2016. Before joining NeoGenomics, Weiss was a pathologist and later laboratory director at Clarient Diagnostic Services.

Dec 02, 2019

Bionano Genomics: Mike Ward

Bionano Genomics CFO Mike Ward has notified the firm of his resignation, effective Dec. 6. "Ward's resignation is not the result of any disagreement with the company," Bionano Genomics said last week in a document filed with the US Securities and Exchange Commission.

Nov 22, 2019

Inteliquet: Marie Lamont

Inteliquet has named Marie Lamont interim president and chief operating officer. She replaces former CEO, President, and COO Carla Balch, who left Inteliquet to "pursue other opportunities," the company said. Lamont had been president of patient services at Dolman Life Science Services. Previously, she held several senior positions at Genzyme. Inteliquet rebranded from TransMed Systems earlier this year.

Nov 21, 2019

NYGC: Mary-Claire King

Mary-Claire King has joined the New York Genome Center faculty on a consulting basis as a senior associate core member. She is the American Cancer Society Professor in the Department of Genome Sciences and Medicine at the University of Washington in Seattle. At the NYGC, she will work closely with Thomas Lehner, the center's recently appointed scientific director of neuropsychiatric disease, and act as a senior adviser to both Lehner and Tom Maniatis, the center's CEO.  

Nov 21, 2019

Elucidata: Richard Kibbey, Nick Pullen, Avi Ma'ayan

Elucidata has formed a scientific advisory board comprising Richard Kibbey, Nick Pullen, and Avi Ma'ayan. Kibbey is associate professor of medicine (endocrinology) and cellular & molecular biology at the Yale School of Medicine. Pullen is the scientific cofounder of Elucidata, and has more than 20 years of experience in the pharmaceutical industry with Pfizer, Roche, and most recently Celgene. Ma'ayan is director of the Mount Sinai Center for Bioinformatics and a professor of bioinformatics in Mount Sinai's Department of Pharmacological Sciences.

ScienceInsider reports that rude and unprofessional paper reviewers are common and can have harmful effects.

The US Senate has confirmed Stephen Hahn as the next commissioner of the Food and Drug Administration, according to the New York Times.

CNBC reports Apple is partnering with Color Genomics to offer its employees free DNA screening for disease.

In Science this week: researchers use CRISPR tool to find gut microbiome molecules involved in immunity, and more.